%0 Journal Article
%T No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease.
%A Botton J
%A Semenzato L
%A Dupouy J
%A Dray-Spira R
%A Weill A
%A Saint-Lary O
%A Zureik M
%J Res Pract Thromb Haemost
%V 6
%N 4
%D May 2022
%M 35755854
%F 5.953
%R 10.1002/rth2.12743
%X <B>UNASSIGNED: </B>Aspirin at low doses has been reported to be a potential drug candidate to treat or prevent severe coronavirus disease 2019 (COVID-19).<BR><B>UNASSIGNED: </B>We aimed to explore whether low-dose aspirin used for primary cardiovascular prevention was associated with a lower risk of severe COVID-19.<BR><B>UNASSIGNED: </B>A large cohort of patients without known cardiovascular comorbidities was constructed from the entire French population registered in national health care databases. In total, 31.1 million patients aged ≥40 years, including 1.5 million reimbursed for low-dose aspirin at least at three time points during the 6 months before the epidemic, were followed until hospitalization with a COVID-19 diagnosis or intubation/death for hospitalized patients.<BR><B>UNASSIGNED: </B>Cox models adjusted for age and sex showed a positive association between low-dose aspirin and the risk of hospitalization (hazard ratio [HR], 1.33; 95% confidence interval (CI), 1.29-1.37]) or death/intubation (HR, 1.40 [95% CI, 1.33-1.47]). In fully adjusted models, associations were close to null (HR, 1.03 [95% CI, 1.00-1.06] and 1.04 [95% CI, 0.98-1.10], respectively).<BR><B>UNASSIGNED: </B>There was no evidence for an effect of low-dose aspirin for primary cardiovascular prevention in reducing severe COVID-19.